Beyond metabolic regulation, Hunt et al. provided evidence for the anti-inflammatory properties of GLP-1 agonists in reducing obesity-related inflammation, thereby expanding the therapeutic range of these agents [59]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.